摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氧杂-5-氮杂-螺[3,5]壬烷 | 1046153-04-1

中文名称
2-氧杂-5-氮杂-螺[3,5]壬烷
中文别名
2-氧杂-5-氮杂螺[3.5]壬烷;2-噁-5-氮杂螺[3,5]壬烷
英文名称
2-oxa-5-aza-spiro[3.5]nonane
英文别名
2-Oxa-5-azaspiro[3.5]nonane
2-氧杂-5-氮杂-螺[3,5]壬烷化学式
CAS
1046153-04-1
化学式
C7H13NO
mdl
MFCD13180592
分子量
127.186
InChiKey
FNTBEHJVXDDFRG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    207.2±15.0 °C(Predicted)
  • 密度:
    1.04±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    21.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934999090

反应信息

  • 作为反应物:
    描述:
    2-氧杂-5-氮杂-螺[3,5]壬烷3-[4-(2-bromo-ethoxy)-3-methoxy-phenyl]-6-(4-chloro-phenyl)-3H-thieno[3,2-d]pyrimidin-4-onecaesium carbonate 、 sodium iodide 作用下, 以 4-甲基-2-戊酮 为溶剂, 反应 20.0h, 以42.5%的产率得到6-(4-chloro-phenyl)-3-{3-methoxy-4-[2-(2-oxa-7-aza-spiro[3.5]non-7-yl)-ethoxy]-phenyl}-3H-thieno[3,2-d]pyrimidin-4-one
    参考文献:
    名称:
    [EN] OXETANE SUBSTITUTED THIENO PYRIMIDINONES
    [FR] THIÉNOPYRIMIDINONES SUBSTITUÉES PAR OXÉTANE
    摘要:
    本发明提供了一种式(I)的化合物或其药学上可接受的盐,其中所述的选择自未取代芳基和杂环芳基群以及取代有Q的芳基和杂环芳基群的群组;Q代表氟、氯、溴、C1-6直链或支链烷基、烷基硫、氰基、三卤代烷基、三卤代烷氧基;Y代表CH或N;R选自氢、C1-6直链或支链烷基、C1-6烷氧基、三卤代烷基、三卤代烷氧基、氨基、烷基氨基、二烷基氨基、羟基氰基、乙酰基、烷基硫和卤素的群组;k独立地是整数2或3;n是0到2的整数,m是1到4的整数,前提是整数m和n的总和等于2到4的整数。该发明还涉及含有它们的药物组合物,用于它们的制备方法,其新的中间化合物以及在治疗和/或预防黑色素浓集激素受体1和可选的H3受体相关疾病或症状中的使用。
    公开号:
    WO2012153154A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL SUBSTITUTED SPIRO-[INDOLINE HETEROCYCLOALKANE] COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS SPIRO-[INDOLINE HETEROCYCLOALKANE] SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE
    申请人:GRUENENTHAL GMBH
    公开号:WO2017108204A1
    公开(公告)日:2017-06-29
    The invention relates to novel spiro-[indoline heterocycloalkane] compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    这项发明涉及新型螺[吲哚杂环烷]化合物,其特征在于该化合物具有通式(I),其中化学基团、取代基、变量和指数如描述中所定义,并且用作药物,特别是用作治疗可以通过抑制PDE4酶来治疗的疾病和病症的药物。
  • [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
    申请人:HARVARD COLLEGE
    公开号:WO2015103583A1
    公开(公告)日:2015-07-09
    Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
    本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II'),以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
  • NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS
    申请人:Grünenthal GmbH
    公开号:EP3527561A1
    公开(公告)日:2019-08-21
    The invention relates to novel substituted pyrimidine compounds of general formula (I) in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    本发明涉及通式 (I) 的新型取代嘧啶化合物 以及它们作为药物的用途,特别是作为治疗可通过抑制 PDE4 酶来治疗的病症和疾病的药物的用途。
  • MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE
    申请人:PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    公开号:US20160326157A1
    公开(公告)日:2016-11-10
    Described herein are monobactam antibiotics of Formula (I), (I′), (II), and (II′), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.
  • [EN] OXETANE SUBSTITUTED THIENO PYRIMIDINONES<br/>[FR] THIÉNOPYRIMIDINONES SUBSTITUÉES PAR OXÉTANE
    申请人:RICHTER GEDEON NYRT
    公开号:WO2012153154A1
    公开(公告)日:2012-11-15
    The present invention provides a compound of Formula (I) or pharmaceutically acceptable salt thereof wherein is selected from the group consisting of unsubstituted aryl and heteroaryl groups and aryl and heteroaryl groups substituted with Q; Q represents fluoro, chloro, bromo, C1-6 straight or branched alkyl, alkylthio, cyano, trihaloalkyl, trihaloalkoxy; Y represents CH or N; R is selected from a group consisting of hydrogen, C1-6 straight or branched alkyl, C1-6 alkoxy, trihaloalkyl, trihaloalkoxy, amino, alkylamino, dialkylamino, hydroxy cyano, acetyl, alkylthio and halo; k is independently an integer 2 or 3; n is an integer from 0 to 2 and m is an integer from 1 to 4 provided that sum of the integers m and n is equal to an integer from 2 to 4. The invention also relates to pharmaceutical compositions containing them, to processes for their preparation, new intermediate compounds thereof and to their use in the treatment and/or prophylaxis of a melanin concentrating hormone receptor 1 and optionally H3 receptor related disease or condition.
    本发明提供了一种式(I)的化合物或其药学上可接受的盐,其中所述的选择自未取代芳基和杂环芳基群以及取代有Q的芳基和杂环芳基群的群组;Q代表氟、氯、溴、C1-6直链或支链烷基、烷基硫、氰基、三卤代烷基、三卤代烷氧基;Y代表CH或N;R选自氢、C1-6直链或支链烷基、C1-6烷氧基、三卤代烷基、三卤代烷氧基、氨基、烷基氨基、二烷基氨基、羟基氰基、乙酰基、烷基硫和卤素的群组;k独立地是整数2或3;n是0到2的整数,m是1到4的整数,前提是整数m和n的总和等于2到4的整数。该发明还涉及含有它们的药物组合物,用于它们的制备方法,其新的中间化合物以及在治疗和/或预防黑色素浓集激素受体1和可选的H3受体相关疾病或症状中的使用。
查看更多